Change clinical practice, catalysing diagnostic stratification in defined diseases: We have identified key points in care pathways where new diagnostics are feasible and maximally impactful. Our integrated regional infrastructure will allow Molecular Pathology to become a focal point for collaborative innovation to scale rapidly into clinical practice.
Increased efficiency and scope of diagnostic tests in stratified medicine: The integrated infrastructure and processes of the Group will enable it to become an efficient test discovery-evaluation-implementation vehicle accessible to other research groups across the biomedical community and diagnostics industry.
Address national-level skills shortages: Integrating academic, clinical and industry training opportunities for example, in Molecular Pathology within existing and bespoke undergraduate/postgraduate programmes to address the identified skills shortages.
We will generate rich sources of data and technologies to feed back into existing basic and translational research programmes and identify novel interdisciplinary research opportunities.
The changes in clinical practice that flow from the implementation of new diagnostics will reduce the burden of illness and the cost of unnecessary treatment on the Irish economy, while at the same time increasing commercial opportunities for industry.
